Posted by Michael Wonder on 04 Aug 2022
ICER publishes evidence report on treatments for amyotrophic lateral sclerosis
4 August 2022 - Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds for cost effectiveness if priced between $9,100 – $30,600 per year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of AMX0035 (Amylyx Pharmaceuticals) and oral edaravone (Mitsubishi Tanabe) for the treatment of amyotrophic lateral sclerosis.
